Comparison of VIA responses across prophylactic HIV-1 vaccine trials
The VIA and ELISpot data described in this work were compared to data generated previously for four candidate HIV-1 vaccine regimens that were designed to elicit HIV-1-specific T cell responses: two of the University of Oxford’s HIVconsv vaccine regimens, the Merck Ad5, and VRC DNA/Ad5 vaccines (Comparison of VIA scores from APPROACH study to the HIV-CORE002, HIV-CORE004, Merck Ad5, and VRC DNA/Ad5 vaccine regimens. (